Commercialization of new biotechnology: A systematic review of 16 commercial case studies in a novel manufacturing sector

Plant Biotechnology Journal

Volumn 13, Issue 8, 2015, Pages 1209-1220

  Paul, Matthew J ^a   Thangaraj, Harry ^a   Ma, Julian K C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Commercialization; Molecular pharming; Plant biotechnology; Spin out

Indexed keywords

BIOTECHNOLOGY; COMMERCIAL PHENOMENA; ECONOMICS; LEGISLATION AND JURISPRUDENCE; MOLECULAR FARMING; PATENT; PRACTICE GUIDELINE; SOCIAL CONTROL;

BIOTECHNOLOGY; COMMERCE; GUIDELINES AS TOPIC; INTELLECTUAL PROPERTY; MOLECULAR FARMING; SOCIAL CONTROL, FORMAL;

EID: 84942191097     PISSN: 14677644     EISSN: 14677652     Source Type: Journal    
DOI: 10.1111/pbi.12426     Document Type: Review

References (24)

1. Decker, E.L. and Reski, R. (2008) Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Bioprocess Biosyst. Eng. 31, 3-9. doi:10.1007/s00449-007-0151-y.
2. Dunmore, C. (2013) Monsanto to grow European seed business after GMO pullout. Reuters Markets, 18th July, http://web.archive.org/web/20140219045926/http://www.reuters.com/article/2013/07/18/monsanto-europe-idUSL6N0FO3TB20130718.
3. FDA News Release 1.5.2012. http://web.archive.org/web/20150116170359/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302549.htm.
4. FDA Safety Alert 13.11.2009. http://web.archive.org/web/20141119094225/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190480.htm.
5. Hiatt, A.C., Cafferkey, R. and Bowdish, K. (1989) Production of antibodies in transgenic plants. Nature, 342, 76-78.
6. Hokusan Co. Ltd. (2013) Interberry alpha product page (in Japanese): http://web.archive.org/web/20150210081807/http://hokusan-kk.jp/info/index.html.
7. KBP Press Release 2.9.2012. http://web.archive.org/web/20150330205907/http://www.kbpllc.com/News/September20083.aspx.
8. Klausner, A. (2005) Biotech venture capital - it's not too late to be early. Nat. Biotechnol. 23, 417-418.
9. Lambert Review of Business-University Collaboration (2003) http://webarchive.nationalarchives.gov.uk/20130129110402/http://www.hm-treasury.gov.uk/consultations_and_legislation/lambert/consult_lambert_index.cfm.
10. Laursen, L. (2012) BASF moves GM crop research to US. Nat. Biotechnol. 30, 204-204.
11. Li, F., Vijayasankaran, N., Shen, A.Y., Kiss, R. and Amanullah, A. (2010) Cell culture processes for monoclonal antibody production. MAbs, 2, 466-479.
12. Ma, J.K., Christou, P., Chikwamba, R., Haydon, H., Paul, M., Ferrer, M.P., Ramalingam, S., Rech, E., Rybicki, E., Wigdorowitz, A., Yang, D.C. and Thangaraj, H. (2013) Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies. Plant Biotechnol. J. 11, 1029-1033.
13. Mimura, C. (2006) Technology licensing for the benefit of the developing world: UC Berkeley's socially responsible licensing program. J. Assoc. Univ. Technol. Manag. XVIII, 15-28.
14. Molowa, D.T. and Mazanet, R. (2003) The state of biopharmaceutical manufacturing. Biotechnol. Annu. Rev. 9, 285-302.
15. Mowery, D.C. and Mitchell, V. (1995) Improving the reliability of the U.S. vaccine supply: an evaluation of alternatives. J. Health Polit. Policy Law, 20, 973-1000.
16. Mueller-Langer (2013) Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?. Health Econ. Policy Law, 8, 185-208.
17. Paul, M.J., Teh, A.Y., Twyman, R.M. and Ma, J.K. (2013) Target product selection - where can molecular pharming make the difference? Curr. Pharm. Des. 19(31), 5478-5485.
18. Sample, I. and Meikle, J. (2003) Brain drain threatens GM crop research. Guardian, 25 September, http://web.archive.org/web/20140912025651/http://www.theguardian.com/science/2003/sep/25/gm.science.
19. Science Insider, Kupferschmidt, K. Using experimental drugs and vaccines against Ebola is ethical, WHO panel says: http://web.archive.org/web/20150418201752/http://news.sciencemag.org/africa/2014/08/using-experimental-drugs-and-vaccines-against-ebola-ethical-who-panel-says.
20. Shaaltiel, Y., Bartfeld, D., Hashmueli, S., Baum, G., Brill-Almon, E., Galili, G., Dym, O., Boldin-Adamsky, S.A., Silman, I., Sussman, J.L., Futerman, A.H. and Aviezer, D. (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J. 5, 579-590.
21. Steere, A.N., Bobst, C.E., Zhang, D., Pettit, S.C., Kaltashov, I.A., Huang, N. and Mason, A.B. (2012) Biochemical and structural characterization of recombinant human serum transferrin from rice (Oryza sativa L.). J. Inorg. Biochem. 116, 37-44.
22. Strasser, R., Stadlmann, J., Schahs, M., Stiegler, G., Quendler, H., Mach, L., Glossl, J., Weterings, K., Pabst, M. and Steinkellner, H. (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6, 392-402.
23. Tekoah, Y., Tzaban, S., Kizhner, T., Hainrichson, M., Gantman, A., Golembo, M., Aviezer, D. and Shaaltiel, Y. (2013) Glycosylation and functionality of recombinant beta-glucocerebrosidase from various production systems. Biosci. Rep. 33, 771-781.
24. Thangaraj, H., van Dolleweerd, C.J., McGowan, E.G. and Ma, J.K. (2009) Dynamics of global disclosure through patent and journal publications for biopharmaceutical products. Nat. Biotechnol. 27, 614-618.